Everest Biolabs Builds the EV Sample-Prep Layer

Everest Biolabs is building laboratory tools for a part of biomarker discovery that rarely gets the headline: preparing a clean, repeatable sample before an expensive analytical instrument starts looking for biological meaning. The Waltham, Massachusetts company develops systems for isolating and measuring extracellular vesicles, or EVs, from complex biological fluids.

George Daaboul, CEO, David Freedman, President and COO, and research leader Tal Gilboa are turning work from David Walt's laboratory at Harvard's Wyss Institute into a commercial platform. Everest's bet is that EV science will need more than sensitive downstream instruments. It will need a sample-preparation layer that can carry purity, yield, and reproducibility across larger studies.

That timing matters. Biomarker programs are moving toward larger cohorts and more automated laboratories, but the biological signal is only as trustworthy as the material placed into the assay. Everest Biolabs is trying to make the handoff from plasma sample to analytical answer less dependent on expert improvisation at a single bench.

About Everest Biolabs

Everest Biolabs was incorporated in 2024 and emerged from stealth in November of that year. The company serves biotech and academic laboratories with a product stack spanning isolation columns, automated instruments, and assays for quantifying EV recovery and contamination.

The leadership team has built in this market before. George Daaboul and David Freedman previously led NanoView Biosciences, an EV-analysis company acquired by Unchained Labs in 2022. Tal Gilboa and Dmitry Ter-Ovanesyan bring the method's scientific lineage, while David Walt connects Everest to a laboratory known for translating measurement science into practical platforms.

That combination gives Everest a recognizable company-building pattern: domain scientists define the analytical problem, experienced operators turn it into a workflow, and a product stack grows around the points where researchers lose time or confidence. The public evidence does not yet establish revenue, customer count, or market share, but it does show a team assembling the pieces needed to compete as laboratory infrastructure rather than a single-product vendor.

The EV Sample-Preparation Problem

Extracellular vesicles are membrane-bound particles released by cells. Their molecular cargo can reflect the tissue or cellular state that produced them, making EVs attractive for biomarker and diagnostic research. Plasma is also packed with albumin, immunoglobulins, lipoproteins, and other material that can travel with an EV fraction and overwhelm the lower-abundance signal.

The result is a four-way trade-off among yield, purity, throughput, and reproducibility. A method can recover more vesicles but carry more contamination. It can produce a cleaner fraction while losing part of the population under study. A manual workflow can perform well in expert hands and still introduce variation when it expands across operators, plates, sites, or hundreds of samples.

The MISEV2023 consensus guidelines treat isolation choices, contaminant assessment, and transparent reporting as core parts of EV interpretation. That is the market opening Everest is pursuing. The company is not selling excitement about vesicles. It is selling more control over what reaches the instrument.

A Platform Across Columns, Instruments, and QC

Everest's commercial stack begins with Apex size-exclusion chromatography columns and extends into automation. The Ascent instrument is designed to process 1 to 8 columns in parallel. The Summit platform moves into plate or column workflows for 4 to 48 samples. Atlas ELISA products give laboratories a way to measure EV recovery and common contaminants.

Those are company-reported specifications, not independent adoption metrics. Strategically, however, the pieces fit together. Columns control the separation step, instruments control timing and handling, and assays create feedback about purity and recovery. A laboratory that can standardize all three has a better chance of distinguishing biological variation from workflow variation.

A 2025 JACS paper by Tal Gilboa, Dmitry Ter-Ovanesyan, and collaborators supports the research lineage for automated, plate-based EV isolation. The work matters because it pushes the method beyond a clever benchtop protocol and toward a format compatible with larger biomarker programs.

Capital for the Commercial and Scientific Build

Everest Biolabs has brought in both private and non-dilutive capital, and the accounting matters. An SEC Form D reports $4.35M sold from a $5.65M equity offering beginning in February 2026. The filing lists 7 investors but does not identify them, assign a round label, or disclose a valuation.

In September 2026, Everest announced a $2.1M multi-year Small Business Innovation Research grant from the National Institute of General Medical Sciences. The NIH RePORTER record lists Tal Gilboa as contact principal investigator, $1,153,043 for the FY2026 budget period, and a project term through August 2028.

The grant funds a defined technical program: combine size-exclusion chromatography with affinity-based depletion of common plasma contaminants, improve the isolation material, adapt it to a 24-well format, and validate higher-throughput processing. The private capital can build the company. The NIH award is tied to proving a specific part of the technology.

Why Everest Biolabs Matters Now

Life-sciences tooling tends to get attention at the most visible endpoint: a sequencer, mass spectrometer, imaging system, or model that names the pattern. Sample preparation lives earlier in the chain, where inconsistency is quieter and can be more expensive. A sophisticated instrument cannot recover information that was lost, diluted, or buried before the run began.

Everest Biolabs matters because it is treating that early layer as a product system. The company is connecting consumables, automation, and quality control around a single workflow. If that system performs consistently across more operators and larger cohorts, it can help researchers decide whether an EV biomarker is real rather than merely interesting under one set of laboratory conditions.

The work remains developmental. Everest has not disclosed audited commercial metrics, and its tools do not prove that any particular biomarker has clinical utility or regulatory approval. The operating test is whether the company can make high-purity EV isolation repeatable enough that another laboratory can trust the result without borrowing the inventor's hands.

That is the larger signal. As biology becomes more computational and measurement systems become more sensitive, the value of disciplined sample preparation rises with them. Everest Biolabs is building in the unglamorous middle, where better data often begins before the data exists.